Abstract
1. DPI 201-106 (DPI) is a novel inotropic agent, with Na+ channel agonistic action combined with a sensitization of contractile proteins to Ca++. In a double-blind trial in healthy volunteers (n = 20) cardiovascular effects (blood pressure, heart rate, ECG) of single oral doses were studied. In addition systolic time intervals (STIs) were assessed in 10 of these subjects. DPI plasma concentrations were measured by h.p.l.c. 2. Preejection period was shortened by 14 ms (P less than 0.01) and 30 ms (P less than 0.01) 1 h after 30 and 60 mg, respectively, suggesting a dose-dependent inotropic effect. Heart rate was slightly reduced after both doses. Mean blood pressure remained unchanged. 3. Corrected QT interval duration (QTc) was prolonged by a mean of 7 ms (NS) and 22 ms (P less than 0.001) 1 h after 30 and 60 mg, respectively. PQ and QRS intervals remained unaffected. 4. Peak plasma levels were attained at 1-2 h and the terminal elimination half-life was approximately 15 h. 5. It is concluded that DPI has positive inotropic and negative chronotropic properties which make it potentially useful for the treatment of heart failure.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Buggisch D., Isenberg G., Ravens U., Scholtysik G. The role of sodium channels in the effects of the cardiotonic compound DPI 201-106 on contractility and membrane potentials in isolated mammalian heart preparations. Eur J Pharmacol. 1985 Dec 3;118(3):303–311. doi: 10.1016/0014-2999(85)90141-4. [DOI] [PubMed] [Google Scholar]
- Gibson D. G. Use of the systolic time intervals in clinical pharmacology. Br J Clin Pharmacol. 1978 Aug;6(2):97–102. doi: 10.1111/j.1365-2125.1978.tb00832.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hassan S., Turner P. Systolic time intervals: a review of the method in the non-invasive investigation of cardiac function in health, disease and clinical pharmacology. Postgrad Med J. 1983 Jul;59(693):423–434. doi: 10.1136/pgmj.59.693.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hof R. P., Hof A. Mechanism of the vasodilator effects of the cardiotonic agent DPI 201-106. J Cardiovasc Pharmacol. 1985 Nov-Dec;7(6):1188–1192. doi: 10.1097/00005344-198511000-00028. [DOI] [PubMed] [Google Scholar]
- Johnson B. F., Meeran M. K., Frank A., Taylor S. H. Systolic time intervals in measurement of inotropic response to drugs. Br Heart J. 1981 Nov;46(5):513–521. doi: 10.1136/hrt.46.5.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
- Scholtysik G., Salzmann R., Berthold R., Herzig J. W., Quast U., Markstein R. DPI 201-106, a novel cardioactive agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilatory properties. Naunyn Schmiedebergs Arch Pharmacol. 1985 May;329(3):316–325. doi: 10.1007/BF00501887. [DOI] [PubMed] [Google Scholar]
- Thormann J., Kramer W., Kindler M., Kremer F. P., Schlepper M. Comparative efficacy of the new cardiotonic agent DPI 201-106 versus dobutamine in dilated cardiomyopathy: analysis by serial pressure/volume relations and "on-line" MVO2 assessment. J Cardiovasc Pharmacol. 1986 Jul-Aug;8(4):749–757. [PubMed] [Google Scholar]
- Weissler A. M., Harris W. S., Schoenfeld C. D. Systolic time intervals in heart failure in man. Circulation. 1968 Feb;37(2):149–159. doi: 10.1161/01.cir.37.2.149. [DOI] [PubMed] [Google Scholar]